Exclusion criteria included a height that was less than 2 SD below the mean or greater than 2 SD above the mean on achondroplasia growth charts ... 11.5), and 58% were female.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for TransCon ® CNP (navepegritide) for the treatment of children with achondroplasia, a rare ...

A promising daily tablet is effective at increasing height and improving proportional limb growth in children with ...

The most common cause of DSS is achondroplasia ... growth rate is declining, a pediatrician looks for signs of failure to thrive. The World Health Organization (WHO) developed growth percentile ...

Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling ...

Additionally, improvements were noted in lower limb alignment, proportional growth, and spinal canal dimensions. Achondroplasia is caused by a variant in the FGFR3 gene and affects over 250,000 ...